May 28, 2019
Pharma14 has been tracking the Russian pharmaceutical market closely and can confirm reports that the number of medicines in the nationally important VED list has increased.
The vital and essential medicine list in Russia includes those drugs that are price regulated and reimbursed, giving equal access.
The overall number of medicines in the vital and essential list has increased approximately by 500 over the last year. This would include various concentrations and pack sizes.
Lately the Russian government has added 35 new molecules to the VED list including Lapatinib and Elsulfavirine.
Furthermore the prices of medicines on the VED list will remain unchanged.
On the manufacturing side, it is reported that 80% of all VED medicines are now manufactured locally.
Sample data: Lapatinib (Tayverb) and Elsulfavirine (Elpida).
May 21, 2019
The EU recently adopted new measures to increase the competitive strength of its generic and biosimilar manufacturers. Regulation (EC) No 469/2009.
This new legislation will grant exceptions to the protection of original medicines (SPC - Supplementary protection certificate) in the case of export or stockpiling for EU 'day-one' entry.
Due to this new rule, EU manufacturers will be allowed to produce generic medicines or a biosimilar versions of a SPC protected medicine while the SPC is still in force, if the purpose of this manufacturing is for export to a non EU country where protection has already expired or never existed previously.
In the case of EU stockpiling, the new measure grants producers the right to start manufacturing during the six month period before SPC expiration.
This new measure will ensure rapid entry into market of generics and biosimilars on expiration day.
May 14, 2019
The HIV medicine market size was valued at US$28 billion in 2018 and has grown at close to 10% since 2014.
With key brand patent expiration's coming in the next 5 years market growth is expected to slow down. A lower CAGR is expected for HIV drugs until 2026 where after growth is expected to become negative.
Growing at 14% for the last 5 years the North American markets accounted for 65% of the overall HIV drug market in 2016. The North American market is expected to continue growing at a lower CAGR of 0.45% for the next 10 years but still account for close to 70% of the total global market.
Pharma14 global medicine index continuously tracks all HIV medicine prices and consumption with standard monthly updates.
Top selling HIV medicines. Germany snapshot. . Atripla, Isentress, Prezista, Stribild, Tivicay, Triumeq, Truvada, Viread.
May 07, 2019
Pharma14 is glad to announce the addition of the United Arab Emirates to its global medicine database.
The United Arab Emirates pharmaceutical market, is currently valued at $2.7 billion.
This figure represents 16.3% of the national healthcare budget.
Patented pharmaceutical spending represents 67.2% of total medicines sold while generics and OTC products are standing at 18.4% and 14.4% respectively.
Rx medicines account for 85.6% of the total pharmaceutical market.
The U.A.E. healthcare market is quickly growing. In 2017, healthcare expenditures in the U.A.E. reached $17 billion and are expected to rise to $21.3 billion by 2021.
Overall healthcare spending is projected to account for 4.6% of a country’s GDP by 2026 from 4.2% in 2016
April 30, 2019
For many companies in the pharmaceutical chain knowing who is the manufacturer of a medicine has an important advantage with many practical uses including business development decisions.
Today's market unique database provider who carries such information is Pharma14.
A few of the advantages of having actual manufacturer information may include:
1. Find CMO's with specific hard to find manufacturing capabilities.
2. Use Pharma14 filtering tools to cross reference manufacturers with administration routes and dosage forms.
3. Cross reference manufacturers vs. MA holders or active ingredients.
4. Map out the connecting parent manufacturer with a specific medicine across multiple countries and regions.
5. Locate manufacturers for direct licensing agreements.
6. Help pharmaceutical companies, API producers and others to seek out partner FDF manufacturers.
Sample data: Spain Dutasteride manufacturers. 0.5 mg capsules.
April 24, 2019
Consumption and sales data of UK prescription medicines for 2018 is now available on Pharma14.
This includes pharmacy and hospital channels for England, Scotland, Wales and N. Ireland.
In overall numbers, the cost of prescriptions dispensed in 2018 was USD 13.54 billion . A small but significant decrease of 3.7% from USD 14.07 billion in 2017
In 2018 as well as in 2017 roughly 1.3 billion medicines were prescribed in the UK with a slight increase of 0.3% from 2017 to 2018.
Sample data: Enoxaparin 100 mg and 150 mg injection consumption and sales.
2017 vs. 2018 data including consumption and sales movement.
Note: Generic Arovi came onto the market in 2018. (Line 8).
April 17, 2019
The orphan drugs market is growing annually at roughly 7%. Total orphan drug sales will rise from $127bn for 2017 to $217bn in 2022.
An orphan drug can be defined as an agent specifically designed to treat rare (orphaned) diseases.
Prior to 1983 R&D of orphan drugs was limited but a US orphan drug act at that time gave incentive to the new development of these medicines.
NORD (The National Organization for Rare Disorders), one of the backers of the original act estimates 30 million Americans suffer from thousands of rare diseases.
The 1983 act paved way for other countries to follow suite, notably the European Union in 2000 and Japan a decade earlier.
The Pharma14, monthly updated, platform tracks and lists all marketing authorizations, including orphan drugs across 41 countries.
Sample data: Orphan drug Nitisinone in German market. 2 mg, 5 mg, 10 mg, 20 mg capsules.
April 02, 2019
March 26, 2019
March 19, 2019
March 12, 2019
March 05, 2019
February 26, 2019
February 19, 2019
February 12, 2019
February 05, 2019
January 29, 2019
January 22, 2019
January 15, 2019
January 08, 2019
January 01, 2019
December 25, 2018
December 18, 2018
Sample data: Japan Tadalafil still sold exclusively by Eli Lilly.
Sample data: Japan Pregabalin still sold exclusively by Pfizer.
December 11, 2018
Is one of your data needs and requirements the reimbursed status of medicines across Europe and other regulated markets?
Pharma14 is happy to announce the total coverage of reimbursed data of all medicines in our database.
As you know reimbursed information is one of those illusive data sets that can change on a constant basis.
Our monthly updated platform will give you total reimbursed information for over 500,000 marketed medicines across 41 countries.
December 04, 2018
Pharma14 is happy to announce the launch of our new 39 country UNDER THE RADAR medicine locator.
This new tool will give you access to medicines that have fallen off patent and are yet to have a competing generic version. The algorithm can also search for medicines with 2,3 or more market competitors.
Looking at the broader market, till today, it was not too clear which drugs had a generic alternative and which didn't. That left room for pharmaceutical companies to market those drugs without any or little competition. Constantly updated, Pharma14's proprietary search feature can help you keep tabs on the pool of drugs with no or very little generic competition. Ideally, other companies can manufacture, in or out license generic alternatives, increasing competition, and becoming a new player in the market.
The following example shows Bezafibrate in France that is sold exclusively by Arrow Generics. Bezafibrate is an older drug coming onto the market in the early 1980's with annual sales in France of approximately USD 4 million.
60 Medinat Hayehudim St.
Entrance C. Third floor.